

Molecular epidemiology of lung cancer and geographic variations

Tetsuya Mitsudomi, MD Division of Thoracic Surgery Kinki University faculty of Medicince Odaka-Sayama, Japan





Disclosure slide

- Advisor to company: AstraZeneca, Novartis, Chugai, Boehringer-Ingeleheim, Pfizer, Roche, Synta, Clovis, MSD
- Lecture fees: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Eli-Lilly, Daiichi-Sankyo
- Research expenses: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Ono, Daiichi-Sankyo, Eli-Lilly





Molecular epidemiology of lung cancer

- Difference in incidence/mortality
- Difference in histologic distribution
- Difference in EGFR/KRAS mutation
- Difference in smoking habit
- Difference in susceptibility to different carcinogens based on SNPs





Lung cancer mortality and smoking rate do not parallel





Adult population smoking daily, 2011

Lung cancer mortality 2011

European Society for Medical Oncology

		_		Mexico	10.0		and the second se	
10.7		-	India	Chile	12.9			
13.1			Sweden South Africa	Gime	/.3	23.0		
1/ 2		-		Fortugal	4.7	28.5		
14.0		-	Brazil	Israel	8.7	30.4		
14.8		-	United States	Sweden	12.9	31.4		
15.1		-N2 + 715 +	Australia	Finland	8.2	32.2		
15.7	_	- * •	Canada	Japan	79	35.9		
16.5			New Zealand	Switzerland	10.9	36.3		
17.0			Luxembourg	Austria	110	27.9		
17.0		- 1	Norway	Australia			0	
18.5				- Australia	14./		•	
18.6		-	Portugal	Estonia	- 6.4		40.4	
18.9		-	Slovenia	Germany	11.3	40.	.5	
19.5			_Slovak Rep. 🔰 🦯	Spain	5.3	40.8		
19.6			nited Kingdom 🛛 🖌	Slovak Republic	8.8		41.4	
19.9		_	Mexico V	V Norway		41.8		
20.0		-	Denmark	/italy	9.2		42.4	
20.1			Japan	France	8.6 Indebidenterinder	42	9	
20.5		-	Relation	Korea	9.3		43.0	
20.8			Netherlands	New 7ealand	10.2	*************	44.0	
20.9		-	OECD34	Slovenia			14.0 • AE O	
21.9			Germany	Grana	10.9		45.0	
22.5		-	Italy	Greece	- 1.3		47.2	
23.2		-	Austria	Czech Republic	12.5		47.9	
23.2		-	France	Luxembourg	12.2		48.9	
23.8			Poland	Viceland	23.9		49 .5	
23.8			Turkev	Ireland	18.6		50.6	
23.9		-	Spain	United Kingdom	20,4		51.3	
24.1			China	Belgium	9.9 padadastastastastasta		54.4	
24.2		-	Indonesia	letherlands	17.5		57.0	
24.0		-	Uzech Rep.	Canada	241		577	
26.5		-	Estonia	United States	04.0	************		0
29.0				Dollard Deland	24.0			0
29.8			Chile	- Polaliu	12.0		1.00.7	
31.9			Greece	Denmark	25.2		65.	.6
33.8			Russian Fed.	Hungary	19.9 Letter			75.6
40	30 20	10 0			0	25	50	75
% of popu	lation aged 15 years and over				R 20			
	J ,					UECD		BETTER MEDICIN BEST PRACTICE
6-29 Ma	rch 2014, Geneva, Switze	erland					IASLC	ean Society for Medical Oncolos



Higher susceptibility to lung cancer in Caucasian smokers than in Asian smokers



Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies

Michael J. Thun^{1*}, Lindsay M. Hannan¹, Lucile L. Adams-Campbell², Paolo Boffetta³, Julie E. Buring⁴, Diane Feskanich⁴, W. Dana Flanders^{1,5}, Sun Ha Jee⁶, Kota Katanoda⁷, Laurence N. Kolonel⁸, I-Min Lee⁴, Tomomi Marugame⁷, Julie R. Palmer⁹, Elio Riboli³, Tomotaka Sobue⁷, Erika Avila-Tang¹⁰, Lynne R. Wilkens⁸, Jon M. Samet¹⁰

- Men had higher death rates from lung cancer than women in all age and racial groups studied
- Male and female incidence rates were similar when standardized across all ages 40? y, albeit with some variation by age
- African Americans and Asians living in Korea and Japan (but not in the US) had higher death rates from lung cancer than individuals of European descent
- No temporal trends were seen when comparing incidence and death rates among US women age 40–69 y during the 1930s to contemporary populations where few women smoke, or in temporal comparisons of neversmokers in two large American Cancer Society cohorts from 1959 to 2004
- Lung cancer incidence rates were higher and more variable among women in East Asia than in othergeographic areas with low female smoking.

Thun et al., PLoS Med., 5(9) e185, 2008





Lung cancer mortality (per 100,000) among <u>current smokers</u> in two cohorts



*Age-standardized to the 2000 IARC World population, ages 40-79, only presented if 10 or more events occurred within specified age-range





EGFR-mutated lung cancer typical of lung cancer in non-smokers occurs independent of smoking



European Lung cancer mortality (per 100,000) among life-long <u>never smokers</u> in individual 6 cohort studies

(Korea x 1, Japan x 1, US x 3)

IASLC



elco



Incidences of EGFR mutations according to patient backgrounds

(compiled from the literature N=2880, Mitsudomi et al., Cancer science 2007)





EGFR Mutation frequency according to ethnic/geographic backgrounds



Shi et al., JTO, 2014; Chougule et al., PLoS One, 2013; Yatabe personal comm, Dogan et al., Clin Cancer Res, 2012, Valee et al., Int J Oncol, 2013, Marchetti et al., JCO, 2005



European Lung Cancer Conference

Smoking rate by sex and countries in

lung cancer cases and controls

Low smoking rate in Asian female lung cancer patietns Control Lung cancer





Incidence of EGFR mutations in Pack-year: Comparison of US data with Japanese data



IASLC



Incidence of driver gene mutations in adenocarcinoma of the lung







Does smoking prevent EGFR mutations?

Case control study at ACC to assess effect of smoking on EGFR mutations

Lung cancer cases 435

152 EGFR mutation, 283 wt

Non-cancer controls 2175

1:5 age-sex matched

Comprehensive life-style data by The Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC)

Matsuo et al., Cancer Science 98:96-101,2007





EGFR mutation occurs independent of smoking! Smoking dilutes EGFR mutated lung cancer by EGFR WT lung cancer

Matsuo et al., Cancer Science 98:96-101,2007





EGFR mutation, smoking and ethnicity





GWAS of lung cancer vs controls

Study	Lung cancer cases (discovery set)*	Controls (discovery set)	Arrays [nos. of SNPs]	Chromosomal regions and main associated genes
Spinola 2007 (24)	335 smokers	338 smokers	Affymetrix [116,204]	10p KLF6
Amos 2008 (25)	1,154 smokers	1,137 smokers	Illumina [317,498]	TSq CHRNAD
Hung 2008 (26)	1,989 smokers	2,625 smokers	Illumina [317,139]	15g CHRNA3 CHRNA5
Liu 2008 (27)	194 with familial lung cancer	219 smokers and	Affymetrix [500,568	15q various genes
		non-smokers	and 906,703]	
Thorgeirsson 2008 (28	3) 1,024 smokers	32,244 controls	Illumina [306,207]	15g CHRNA2
McKay 2008 (29)	3,259 smokers	4,159 smokers	Illumina [315,194]	Sp TERT-CLPTMIL 15q CHRNA3
Wang 2008 (30)	1,952 smokers	1,438 smokers	Illumina [511,919]	5p CLPTMT, 6p BAT3-MSH5, 15q CHRNA3
Broderick 2009 (31)	1,978 smokers, and meta-analysis	1,438 smokers, and	Meta-analysis	5p TERT-CUPTMIL, 6p BAT3-MSH5, TNKB, 15q
Landi 2009 (32)	5,739 smokers	5,848 smokers	Illumina [515,922]	Sp TERT-CLPTMIL, 15g CHRNA3
Hsiung 2010 (33)	584 cases (never smoking females	585 controls (never	Illumina [610.901]	ODIS TERT-CAPTMIL
	with lung adenocarcinoma)	smoking females)		
Li 2010 (34)	377 never smokers	377 never smokers	Illumina [373,397 and 592,532]	13q31.3 GPC5
Miki 2010 (35)	I,004 with lung adenocarcinoma	1,900 controls	Illumina [610,901]	3q28 TP63, 5p15 TERT
Yoon 2010 (36)	621 cases (smokers and never	1.541 controls (smokers	Affymetrix [500,568]	3q29 C3orf21, Sp TERT-CLPTMIL
	5p15 TE			
Hu 2011 (37)	2,301	VI CLI HIVIIL	,ux [906,703]	3q28 TPG3, 5p15 TERT CLPTMIL, 13q12 MIPEP-
	smokers)	and never smokers)		TNFRSF19, 22q12 MTMR3-HORMAD2-LIF
Ahn 2012 (38)	15025		iv [906,703]	18p11 FAM38B
Dong 2012 (39)	IJQZJ	CHINIAS	[906,703]	12q23 SLC17AS NRIH4
Lan 2012 (40)	5,510 never-smoking female lung	4,544 controls	Various	3q28 TP63, 5p15, 6p21 HLA, 6q22 ROSI, DCBLDI,
	cancer cases			10q25 VTIIA, 17q24 BPTF
Shiraishi 2012 (41)	1,722 cases (smokers and never	5,846 controls (smokers	Illumina [709,857]	3q28 TP61, 5p15 TERT, 5p21 BTNL2, 17q24 BPTF
	smokers)	and never smokers)		
Timofeeva 2012 (42)	Meta-analysis: 14,900 cases	29,485 controls (smokers	Various	5p15, 6p2, 15g25 for MCLC; 9p21 for SCC
King 2012 (42)	(smokers and never smokers)	and never smokers)	Aff	
Kim 2013 (43)	205 remaie never smokers with lung	1,455 CONTROIS	Anymetrix [440,/94]	2p16 NKXN1
	Cancer			

Yang IA, Holloway JW, Fong KM: Genetic susceptibility to lung cancer and co-morbidities. J Thorac Dis 5:S454-S462, 2018: 26-29 March 2014, Geneva, Switzerland



5p15: Consistent results between Western and Asians



* p<0.05, Troung T, et al., JNCI, 102:959-971, 2010)

rs2736100: teromerase reverse transcriptase gene (*TERT*) rs407210: cleft lip and plate transmembrane1-like gene (*CLPTM1L*)





15q25: inconsistent results between Western and Asians

Per-allele models of the logistic regression



Troung T, et al., JNCI, 102:959-971, 2010) rs16969968: nicotine acetylcholine receptor α5 gene (*CHRNA3*) rs8034194: (*LOC123688*)





Effect of smoking on the risk of lung cancer was stronger in with 15q25 risk allele carriers in Japanese population.

P for interaction : 0.021

IASLC



* p<0.05

Association between a GWAS identified locus and the risk of lung cancer in Japanese Population Ito H, et al. JTO 7:790-797, 2012



What makes Asian people susceptible for EGFR mutation?





Polymorphisms within the EGFR gene

- CA-SSR1(CA simple sequence repeat 1) in intron 1
 - East-Asians have longer repeats (Liu et al, CCR 2003)
 - Shorter repeats are associated with increased transcription and protein expression (Gebhardt, JBC 1999, gebhardt Hitol Hist Pathol 2000)
- 2 SNPs in the promoter lesion with increased transcription and expression of EGFR mRNA
 - -216(G/G to G/T or T/T)
 - SP1 binding site
 - Less common in Asians (Liu, Cancer Res 2005)
 - -191(C/C to C/A or A/A)
 - Promoter regions
 - Less common in Asians(Liu, Cancer Res 2005)



CA-SSR1: ethnic difference, transcription and expression



IASLC

Polymorphisms, Mutations, and Amplification of the *EGFR* Gene in Non-Small Cell Lung Cancers

Masaharu Nomura¹, Hisayuki Shigematsu¹, Lin Li², Makoto Suzuki¹, Takao Takahashi¹, Pila Estess³, Mark Siegelman³, Ziding Feng², Harubumi Kato⁴, Antonio Marchetti⁵, Jerry W. Shay⁶, Margaret R. Spitz⁷, Ignacio I. Wistuba⁸, John D. Minna^{1,9,10}, Adi F. Gazdar^{1,3*} PLOS Med 4(4): e125, 2007

- Variant forms of SNP216 (G/T or T/T) and SNP191 (C/A or A/A) (associated with higher protein production in experimental systems) were less frequent in East Asians than in individuals of other ethnicities (p<0.001).
- Both alleles of CA-SSR1 were significantly longer in East Asians than in individuals of other ethnicities (p < 0.001).

Asians→longer repeat→low protein

IASLC

These findings suggest that the cells of most East Asians make less EGFR protein than do the cells of individuals of other ethnicities. If a certain critical level of EGFR is required to drive the cell toward a malignant phenotype, mutations of the TK domain and autonomous activation of downstream signaling may target East Asians, the subgroup with possibly lower intrinsic protein production.



Preliminary results of GWAS for EGFR mutated lung cancer

- Purpose
 - To explore genomic locus that explains difference in incidence of EGFR mutations between Japanese and Caucasians
- Materials and Methods
 - Collaborative GWAS study for NSCLC with confirmed EGFR mutational status
 - GWAS using whole genome scan data obtained by Illumina 610Quad
 - Five Centers
 - Aichi Cancer Center
 - Kyoto University
 - Okayama University
 - Hyogo University
 - Kagawa University
 - Multi-phase study
 - Phase I: Screening phase
 - Phase II: Validation phase

Courtesy of Prof. K. Matsuo@Kyushu University/Aichi Cancer Center



Phase I analysis



- Illumina platform.
 - 6 millions of SNPs
 - Screen for loci for
 - EGFR mut. LC
 - EGFR wt. LC
- Genotyping is on-going.
- In this presentation, preliminary results in ACC data are shown
 - Case-Control study
 - Cases: 118 EGFR mutated lung adenocarcinoma treated at ACC

IASLC

 Controls: Non-cancer control 1194

Courtesy of Prof. K. Matsuo@Kyushu University/Aichi Cancer Center



Manhattan plot (ACC cohort) <u>EGFR mutated</u> LC vs. control

2 significant and 2 marginally significant loci for EGFR mutated lung cancer were identified.



 chrom. 2 chrom. 3 chrom. 4 chrom. 5 chrom. 6 chrom. 7 chrom. 8 	 chrom. 10 chrom. 11 chrom. 11 chrom. 19 chrom. 12 chrom. 20 chrom. 13 chrom. 21 chrom. 14 chrom. 22 chrom. 15 chrom. X chrom. 16 chrom. Y
• chrom. 1	• chrom. 9 • chrom. 17

After QC and GC.

Courtesy of Prof. K. Matsuo@Kyushu University/Aichi Cancer Center



Comparison of allele freq. of risk allele in HapMap database.



- ORs for having risk allele for two of four loci were around 3.
- Allele freq. of risk allele for these loci is common in Japanese than in Caucasian.
- This is accordant with the fact EGFR mut lung cancer is more prevalent in Japanese than in Caucasian.

Courtesy of Prof. K. Matsuo @Kyushu University/Aichi Cancer Center



Conclusions

- In smokers, the risk for lung cancer is higher in Caucasians, while in never smokers, the risk is higher in Asians
- EGFR mutations are dependent on smoking status, ethnicities, sex and histologic types
- Risk for EGFR mutated lung cancer is independent of smoking dose.
- Three polymorphisms within the EGFR gene is responsible for lower EGFR protein level in Asians that may be relevant to high EGFR mutation rate
- GWAS reproducibly identified risk alleles at 5p15 and 15q25 in Caucasians.
- While 5p15 allele has similar effect on both Caucasians and Asians, effect of 15q25 appears different
- Preliminary GWAS efforts revealed several loci that is significantly associated with EGFR mutated lung cancer which is more frequent in Asians

